Axxam offers access to the entirely new generation screening collection AXXDIV4.0 for hit identification programs. The collection consists of around 325,000 drug-like and lead-like compounds whose selection was carried out building on Axxam’s broad screening expertise, with significant input given by the company’s team of medicinal and computational chemists. The goal was to ensure that the identified screening hits could represent promising and favorable starting points for further optimization. Only compounds that have been available on the market for less than five years were considered in the selection process.
In order to meet the manifold needs of customers, the new screening collection AXXDIV4.0 includes four different subsets (no overlap):
- Discovery set: ~179K lead-like molecules, mean of 15 analogues for each chemotype. Provides SAR information
- ExplorerPLUSset: ~98K lead-like singletons. High coverage of diversity. Ideal for novel peripheral and central targets. Size doubled in April 2019
- Probe set: ~12K Decorated fragment-like compounds, characterized by lower MW. Ideal starting point for structure-enabled programs
- CNS set: ~35K lead-like singletons, characterized by optimized MPO scores and specifically biased for CNS, pain and intracellular targets
AXXDIV4.0 is available for screening and for selection of compounds for hit expansion.